Rotavirus vaccine RIX4414 (Rotarix®): a guide to its use in preventing rotavirus gastroenteritis in the EU
- First Online:
- Cite this article as:
- Harrison, T.S., Lyseng-Williamson, K. & Plosker, G.L. Drugs Ther Perspect (2013) 29: 130. doi:10.1007/s40267-013-0034-z
The human monovalent rotavirus vaccine RIX4414 (Rotarix®) is indicated for the prevention of rotavirus gastroenteritis (RVGE) in infants aged 6 to 24 weeks in the EU. It offers broad sustained protective efficacy against RVGE including severe cases, and reduces the incidence of associated hospitalizations. It does not interfere with the immunogenicity of other paediatric vaccinations, and is considered safe.